Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 16;81(2):e15-e26.
doi: 10.1093/cid/ciaf334.

State-of-the-Art Review: Hepatitis C

Vincent Lo Re 3rd  1 , Debika Bhattacharya  2 , Jennifer C Price  3 , Andrew Aronsohn  4 , H Nina Kim  5 , Oluwaseun Falade-Nwulia  6 , Matty Zimmerman  7 , Stacey Trooskin  8 , Jessie Torgersen  1
Affiliations
Review

State-of-the-Art Review: Hepatitis C

Vincent Lo Re 3rd et al. Clin Infect Dis. .

Abstract

Hepatitis C virus (HCV) infection remains a major cause of chronic liver disease and premature mortality worldwide. The World Health Organization and US Department of Health and Human Services have committed to eliminating HCV infection as a major public health threat by 2030, as defined by a 90% reduction in incidence of new HCV infections and 65% reduction in mortality from a 2015 baseline. To help to achieve HCV elimination, it will be necessary to increase HCV screening and increase uptake of HCV treatment, particularly within primary care, correctional, and substance use treatment settings. In this review, we provide strategies for healthcare providers to implement in their practice to enhance patients' completion of the steps of the HCV care cascade. Improving successful completion of each step of the cascade will help alleviate the burden of HCV infection and make the 2030 HCV elimination goals a reality.

Keywords: HCV elimination; HCV infection; cascade of care; direct-acting antiviral therapy; hepatitis C virus.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. V. L. R. received grant funding from GlaxoSmithKline. D. B. received grant funding from Gilead. J. C. P. received grant funding from AbbVie, Genentech, and Gilead. O. F. N. received grant funding from AbbVie and Advisory fees from Gilead. S. T. received advisory fees from Gilead. All other authors report no potential conflicts.

Substances